Live tape
Top 8, mentions 7d6,927NVDA1,188 mentions▲ +0.10AVGO1,010 mentions▲ +0.05GOOGL990 mentions▲ +0.04NKE979 mentions+0.01LULU931 mentions▲ +0.03TSLA794 mentions▲ +0.06META552 mentions▲ +0.06MSFT483 mentions▲ +0.07

Equity · Healthcare

APGE

Apogee Therapeutics, Inc. · NasdaqGM

$135.08 +0.04% 1D Finazon · prior-day close · Sep 2, 2026
Price · Chart
Our own end-of-day closes 59 sessions
$140 $80 10 Jun 2 Sep

The line runs $82.57 on 10 June through $135.08 on 2 September, on a scale from $80 to $140. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of APGE over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 59 sessions over that window: $82.57 on 10 June 2026 through $135.08 on 2 September 2026.

Market cap $9.8B
52-week range $36.35 – $135.08
Avg volume 136.2K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 7, 2026

APGE insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 3 Sep 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 8

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
03 Sep 2026 Shah Nimish P Director Other 1,750,000 $236.44M
03 Sep 2026 HENDERSON MICHAEL THOMAS Chief Executive Officer Other 920,941
03 Sep 2026 Henderson Jane Chief Financial Officer Other 158,371
03 Sep 2026 Fox Jennifer A. Director Other 34,824
03 Sep 2026 Dambkowski Carl Chief Medical Officer Other 167,123
03 Sep 2026 JONES WILLIAM A JR Director Other 34,824
03 Sep 2026 McKenna Mark C. Director Other 20,000
02 Sep 2026 Dambkowski Carl Chief Medical Officer Other 1,375 $186K

APGE reported financials

SEC EDGAR XBRL

APGE reported net income of −$255.8M for the fiscal year ended 31 Dec 2025.

Figure Reported Period
Net income −$255.8M 31 Dec 2025 fiscal year
Diluted EPS −$4.22 31 Dec 2025 fiscal year
Total assets $1.3B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

APGE earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-1.14 —
31 Mar 2026 Q1 2026 $-1.06 —
31 Dec 2025 FY 2025 $-4.22 —
30 Sep 2025 Q3 2025 $-1.11 —
30 Jun 2025 Q2 2025 $-1.13 —
31 Mar 2025 Q1 2025 $-0.95 —
31 Dec 2024 FY 2024 $-3.30 —
30 Sep 2024 Q3 2024 $-0.86 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

APGE institutional holders

SEC Form 13F

13 of the 45 institutional funds we track reported a APGE position for the quarter ended 30 Jun 2026 — a combined $641.6M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Balyasny Asset Management Added +279.6% shares 1,665,102 $221.0M
Millennium Management Added +1,510.7% shares 1,491,404 $198.0M
Soros Fund Management New position 564,500 $74.9M
Man Group Added +849.4% shares 397,000 $52.7M
D. E. Shaw & Co. Added +318.3% shares 246,086 $32.7M
Renaissance Technologies New position 146,800 $19.5M
Two Sigma Investments Trimmed −66.3% shares 94,759 $12.6M
Marshall Wace Held (±25%) −3.4% shares 77,475 $10.3M
Point72 Asset Management New position 54,559 $7.2M
Citadel Advisors Trimmed −92.7% shares 43,857 $5.8M

Showing the 10 largest of 13 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

APGE fails-to-deliver

SEC CNS data

On 11 Aug 2026, 26 shares of APGE failed to deliver (about $4K) — the latest of 3 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
11 Aug 2026 26 $4K <0.001%
10 Aug 2026 8 $1K <0.001%
07 Aug 2026 28 $4K <0.001%
05 Aug 2026 1 $134 <0.001%
04 Aug 2026 3 $402 <0.001%
30 Jul 2026 3,718 $499K 0.005%
29 Jul 2026 17 $2K <0.001%

Source: SEC fails-to-deliver (CNS) data